Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
WVE Stock Forecast 2025-2026
$7.49
Current Price
$1.25B
Market Cap
Buy 14
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to WVE Price Targets
+380.6%
To High Target of $36.00
+153.7%
To Median Target of $19.00
+20.2%
To Low Target of $9.00
WVE Price Momentum
+1.1%
1 Week Change
-4.7%
1 Month Change
-50.9%
1 Year Change
-39.5%
Year-to-Date Change
-52.4%
From 52W High of $15.72
+41.9%
From 52W Low of $5.28
📊 TOP ANALYST CALLS
Did WVE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if WaVe is one of their latest high-conviction picks.
Latest WVE Stock Price Targets & Analyst Predictions
Based on our analysis of 23 Wall Street analysts, WVE has a bullish consensus with a median price target of $19.00 (ranging from $9.00 to $36.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $7.49, the median forecast implies a 153.7% upside. This outlook is supported by 14 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joon Lee at Truist Securities, projecting a 380.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WVE Analyst Ratings
14
Buy
1
Hold
0
Sell
WVE Price Target Range
Low
$9.00
Average
$19.00
High
$36.00
Current: $7.49
Latest WVE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WVE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 11, 2025 | Wedbush | Yun Zhong | Outperform | Maintains | $20.00 |
| Nov 11, 2025 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $16.00 |
| Oct 15, 2025 | Clear Street | Bill Maughan | Buy | Initiates | $22.00 |
| Sep 4, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $18.00 |
| Sep 3, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Reiterates | $22.00 |
| Aug 4, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Initiates | $19.00 |
| Jul 31, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $21.00 |
| Jul 28, 2025 | Oppenheimer | Cheng Li | Outperform | Initiates | $24.00 |
| Jul 16, 2025 | Citigroup | Samantha Semenkow | Buy | Initiates | $16.00 |
| Jun 23, 2025 | Wedbush | Yun Zhong | Outperform | Reiterates | $18.00 |
| Jun 11, 2025 | Raymond James | Michael Freeman | Outperform | Assumes | $14.00 |
| Apr 29, 2025 | Cantor Fitzgerald | Steven Seedhouse | Overweight | Initiates | $10.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Mar 5, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Feb 25, 2025 | Jefferies | Roger Song | Buy | Initiates | $26.00 |
| Nov 21, 2024 | Mizuho | Salim Syed | Outperform | Maintains | $22.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Nov 12, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $36.00 |
| Nov 4, 2024 | B. Riley Securities | Madison El-Saadi | Buy | Maintains | $22.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
Wave Life Sciences Ltd. (WVE) Competitors
The following stocks are similar to WaVe based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
WVE
WaVe Life Sciences
mkt cap
1.25B
Wave Life Sciences Ltd. (WVE) Financial Data
Wave Life Sciences Ltd. has a market capitalization of $1.25B with a P/E ratio of -10.7x. The company generates $109.23M in trailing twelve-month revenue with a -111.6% profit margin.
Revenue growth is -12.5% quarter-over-quarter, while maintaining an operating margin of -740.7% and return on equity of -86.5%.
Valuation Metrics
Market Cap
$1.25B
Enterprise Value
$1.08B
P/E Ratio
-10.7x
PEG Ratio
0.3x
Price/Sales
11.5x
Growth & Margins
Revenue Growth (YoY)
-12.5%
Gross Margin
N/A
Operating Margin
-740.7%
Net Margin
-111.6%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+15.7%
Current Ratio
2.5x
Debt/Equity
14.9x
ROE
-86.5%
ROA
-28.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Wave Life Sciences Ltd. (WVE) Business Model
About Wave Life Sciences Ltd.
What They Do
Develops stereopure nucleic acid therapies.
Business Model
Wave Life Sciences operates in the biotechnology sector, focusing on the research and development of innovative RNA-modulating therapies aimed at treating genetic diseases. The company generates revenue through partnerships, collaborations, and potential commercialization of its therapies, leveraging its unique platform to create high-efficacy treatments.
Additional Information
The company targets serious diseases, particularly those affecting the central nervous system, and aims to address unmet medical needs within the biopharmaceutical industry. Wave Life Sciences positions itself as a pioneer in precision medicine and actively collaborates with various stakeholders to advance therapeutic development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
287
CEO
Dr. Paul B. Bolno M.B.A., M.D.
Country
Singapore
IPO Year
2015
Website
wavelifesciences.comWave Life Sciences Ltd. (WVE) Latest News & Analysis
Latest News
Quick Summary
Wave Life Sciences Ltd. focuses on RNA-based treatments for AATD, obesity, DMD, and Huntington's Disease. It holds a speculative Buy rating, with key clinical readouts expected in 2026.
Why It Matters
Wave Life Sciences Ltd.'s speculative Buy rating highlights potential upside from its unique RNA-based therapies, despite risks from limited data and cash burn, making it a risky investment opportunity.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Wave Life Sciences Ltd (NASDAQ: WVE) announced third-quarter financial results that fell short of expectations.
Why It Matters
Worse-than-expected financial results can signal potential operational issues or declining performance, leading to decreased investor confidence and possible stock price declines for Wave Life Sciences.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Wave Life Sciences Ltd. will hold its Q3 2025 earnings call on November 10, 2025, at 8:30 AM EST, featuring key executives and analysts from various firms.
Why It Matters
Wave Life Sciences' Q3 earnings call indicates key financial and operational updates, impacting stock performance and investor sentiment regarding its growth potential and strategic direction.
Source: Seeking Alpha
Market Sentiment:
Neutral
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
28 days ago
Quick Summary
WAVE Life Sciences' WVE-007 showed up to 85% reduction in Activin E in obesity trials. Cash reserves of $196.2M extend runway to Q2 2027. Investor call scheduled for today at 8:30 a.m. ET.
Why It Matters
WVE-007's positive trial results for obesity suggest strong market potential, while robust cash reserves extend operational runway, enhancing investor confidence in the company's growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Wave Life Sciences reported a quarterly loss of $0.32 per share, slightly worse than the expected loss of $0.30. This compares to a loss of $0.47 per share in the same quarter last year.
Why It Matters
Wave Life Sciences' quarterly loss exceeded expectations, indicating potential operational challenges. However, the reduced loss compared to last year may signal progress, impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Wave Life Sciences Ltd. (Nasdaq: WVE) will participate in two investor conferences in November, highlighting its focus on RNA medicines in the biotechnology sector.
Why It Matters
Wave Life Sciences' participation in investor conferences signals potential updates on its RNA medicines, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About WVE Stock
What is Wave Life Sciences Ltd.'s (WVE) stock forecast for 2026?
Based on our analysis of 23 Wall Street analysts, Wave Life Sciences Ltd. (WVE) has a median price target of $19.00. The highest price target is $36.00 and the lowest is $9.00.
Is WVE stock a good investment in 2026?
According to current analyst ratings, WVE has 14 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WVE stock?
Wall Street analysts predict WVE stock could reach $19.00 in the next 12 months. This represents a 153.7% increase from the current price of $7.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Wave Life Sciences Ltd.'s business model?
Wave Life Sciences operates in the biotechnology sector, focusing on the research and development of innovative RNA-modulating therapies aimed at treating genetic diseases. The company generates revenue through partnerships, collaborations, and potential commercialization of its therapies, leveraging its unique platform to create high-efficacy treatments.
What is the highest forecasted price for WVE Wave Life Sciences Ltd.?
The highest price target for WVE is $36.00 from Joon Lee at Truist Securities, which represents a 380.6% increase from the current price of $7.49.
What is the lowest forecasted price for WVE Wave Life Sciences Ltd.?
The lowest price target for WVE is $9.00 from at , which represents a 20.2% increase from the current price of $7.49.
What is the overall WVE consensus from analysts for Wave Life Sciences Ltd.?
The overall analyst consensus for WVE is bullish. Out of 23 Wall Street analysts, 14 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $19.00.
How accurate are WVE stock price projections?
Stock price projections, including those for Wave Life Sciences Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 9:26 PM UTC